A panel of expert physicians from satellite clinics of MD Anderson review recent updates in the treatment of multiple myeloma and discuss how emerging evidence is applied to their clinical practice.
EP. 1: Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple MyelomaMay 15th 2023
Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.
EP. 3: Treatment of MM: Value of Tumor Boards in PracticeMay 22nd 2023
Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.
EP. 4: Treatment Paradigm for Patients With Transplant Ineligible NDMMMay 22nd 2023
Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.
EP. 5: Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaMay 29th 2023
Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.
EP. 6: Expanding the Treatment Armamentarium in RRMM with Novel TherapiesMay 29th 2023
Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.
EP. 7: RRMM: Access to Bispecifics and CAR T-Cell Therapy in Satellite CampusesJune 5th 2023
A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.
EP. 8: Dosing and Sequencing Bispecifics and CAR T-Cell Therapies in R/R MMJune 5th 2023
Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.